Drugs / JNJ-80038114
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05441501 | Nov 2022 → Mar 2024 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-80038114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05441501 ↗ |
| Route | Subcutaneous | “JNJ-80038114 was administered subcutaneously every 3 weeks (Q3W), starting at 0.1 mg.” PMID 41493473 ↗ Jan 2026 |